Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) (BSIG-H303)

Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD89 and anti-EGFR parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.

Datasheet

Specifications

Targets

CD89 & EGFR

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD89

Host Animal 1

Human

Target 2

EGFR

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors

Targets

Target 1

CD89

Gene ID

2204

UniProt ID

P24071

Alternative Names

FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor

Target 2

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Email: